Eczema Drug's inner workings revealed in small study
NCT ID NCT03293030
First seen Nov 14, 2025 · Last updated May 22, 2026 · Updated 22 times
Summary
This study looked at how dupilumab affects the immune and genetic activity inside eczema skin lesions. Seventeen adults with moderate-to-severe eczema received the drug, and researchers measured changes in immune cells and gene activity over 12 weeks. The goal was to understand how the treatment works at a cellular level, not to test if it works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
UCSF Psoriasis and Skin Treatment Center
San Francisco, California, 94118, United States
Conditions
Explore the condition pages connected to this study.